Multigenic panels in breast cancer: clinical utility and management of patients with pathogenic variants other than BRCA1/2
A Fabi, L Cortesi, S Duranti, EL Cordisco… - Critical Reviews in …, 2024 - Elsevier
Multigene panels can analyze high and moderate/intermediate penetrance genes that
predispose to breast cancer (BC), providing an opportunity to identify at-risk individuals …
predispose to breast cancer (BC), providing an opportunity to identify at-risk individuals …
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort
I Vanni, L Pastorino, V Andreotti, D Comandini… - Journal of Translational …, 2024 - Springer
Background Comprehensive next-generation sequencing is widely used for precision
oncology and precision prevention approaches. We aimed to determine the yield of …
oncology and precision prevention approaches. We aimed to determine the yield of …
[HTML][HTML] The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification
KRN Abadi, C Dupain, I Guillou, R Sanchez… - ESMO Real World Data …, 2024 - Elsevier
Background The European Society of Medical Oncology Scale for Clinical Actionability of
Molecular Targets (ESCAT) classification system provides a standardized framework for …
Molecular Targets (ESCAT) classification system provides a standardized framework for …
[HTML][HTML] Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB …
VD de Jager, P Plomp, MS Paats, S van Helvert… - ESMO open, 2024 - Elsevier
Purpose Molecular tumor boards (MTBs) are considered beneficial for treatment decision
making for patients with cancer with uncommon, rare, or complex mutational profiles. The …
making for patients with cancer with uncommon, rare, or complex mutational profiles. The …
[引用][C] Molecular Tumor Boards: On the evolution of species
P Giacomini, G Ciliberto - European Journal of Cancer, 2024 - ejcancer.com
Molecular Tumor Boards (MTBs) assign off-label, genome-informed treatment to advanced
cancer patients lacking approved therapy options. This approach was first described 13 …
cancer patients lacking approved therapy options. This approach was first described 13 …